Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference
Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference
PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty and Adductoplasty Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am PT.
佛罗里达州庞特维德拉，2025年1月2日（全球新闻通讯社）—— Treace Medical Concepts, Inc.（“Treace”或“公司”）（NasdaqGS: TMCI）是一家医疗科技公司，通过其旗舰的Lapiplasty和Adductoplasty程序推动脚部畸形及相关中足畸形手术治疗的根本变革。万亿.day宣布，首席执行官John T. Treace将于2025年1月14日（星期二）在第43届摩根大通医疗健康会议上发言，发言时间大约为太平洋时间上午9:00。
A live webcast and replay of the fireside chat will be available on the Company's investors relations website at
公司投资者关系网站将提供现场网络广播及对话回放。
Internet Posting of Information
Treace routinely posts information that may be important to investors in the "Investor Relations" section of its website at . The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
信息的互联网发布
Treace定期在其网站的“投资者关系”部分发布可能对投资者重要的信息。公司鼓励投资者和潜在投资者定期查阅Treace网站获取有关Treace的重要信息。
About Treace Medical Concepts
关于Treace Medical Concepts：Treace Medical Concepts， Inc.是一家医疗技术公司，旨在推进外科管理拇趾外翻及相关足弓畸形的护理标准。拇趾外翻是一种复杂的三维畸形，源于足部中部的不稳定关节，影响约6700万美国人，其中Treace估计有110万人需要每年手术治疗。 Treace开创并取得了Lapiplasty 3D Bunion Correction System的专利--这是一种由仪器、植入物和外科方法组成的组合，旨在通过外科手术矫正拇趾畸形的三个平面，并固定不稳定的关节，解决拇趾畸形的根本原因，帮助病人恢复活力的生活方式。为了进一步支持拇趾畸形患者的需求，Treace推出了Adductoplasty Midfoot Correction System，旨在重复性外科手术矫正足弓畸形，以及其Hammertoe PEEk Fixation System，旨在解决锤趾、鸡爪趾和槌状趾畸形。该公司通过推出SpeedPlate Rapid Compression Implants扩大了其足踝市场份额--这是一种具有广泛适用性的创新固定平台，可应用于Lapiplasty和Adductoplasty手术，以及足部其他常见骨融合手术。有关更多信息，请访问网站。
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty 3D Bunion Correction System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty and Adductoplasty procedures, as well as other common bone fusion
Treace医疗概念公司是一家医疗科技公司，旨在提升外科治疗拇外翻及相关中足畸形的护理标准。拇外翻是一种复杂的三维畸形，源于位于脚中部的不稳定关节，影响大约6700万美国人，其中Treace估计每年有110万是手术候选人。Treace开发并申请了Lapiplasty 3D拇外翻矫正系统的专利，这是一种结合了仪器、植入物和外科方法的系统，旨在手术纠正拇外翻畸形的三个平面，并稳固不稳定的关节，解决拇外翻的根本原因，帮助患者恢复活跃的生活方式。为了进一步支持拇外翻患者的需求，Treace推出了其Adductoplasty中足矫正系统，旨在实现中足畸形的可重复外科修正。该公司继续在足部和脚踝市场扩大影响力，推出其SpeedPlate快速压缩植入物，这是一种创新的固定平台，具有广泛的适用性，适用于Lapiplasty和Adductoplasty手术，以及其他常见的骨融合手术。
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
欲了解更多关于Treace的信息，请在LinkedIn、X、Facebook和Instagram与我们联系。
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
联系方式：
Treace Medical Concepts
马克·L·海尔
首席财务官
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
投资者：
吉尔马丁集团
薇薇安·塞万提斯
IR@treace.net
